Global Markets for Neglected Tropical Disease Treatments

  • ID: 4311014
  • Report
  • Region: Global
  • 161 Pages
  • BCC Research
15 % OFF
until Jun 30th 2018
1 of 6
The Global Market for Neglected Tropical Diseases Should Reach $2.6 Billion by 2021 from $1.4 Billion in 2016 at a CAGR of 14.1%

FEATURED COMPANIES

  • Bayer
  • Butantan
  • Eisai
  • Gilead Sciences
  • Glaxosmithkline
  • Merck
  • MORE

Report Includes

  • An overview of the global markets for tropical disease treatments.
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • A look at the total addressable market, an indication of the number of people affected, and the current shares of key marketed therapies.
  • Representations of market shares by geography, company, and future outlook.
  • Insight on some of the newer drug candidates, clinical trials, and their end points.
  • Analyses of factors such as increases in resistance of vectors to common insecticides, increases in rapid diagnostic techniques, and no established treatment for newer conditions like Zika.
  • Profiles of major players in the industry.

Report Scope

The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of nonbranded generics.

Products used for diagnosis as well as PCR techniques, kits and testing facilities are also excluded from the report.

The markets have been categorized based on regions defined by the WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships. Regions include Africa, Americas, South-East Asia, Europe, Eastern Mediterranean and Western Pacific. These cover all the WHO participating countries which are described in detail in the subsequent section.

READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Bayer
  • Butantan
  • Eisai
  • Gilead Sciences
  • Glaxosmithkline
  • Merck
  • MORE

1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing this Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown

2: Summary and Highlights

  • Table Summary : Global Market for Neglected Tropical Diseases, by Indication, Through 2021
  • Figure Summary : Global Market for Neglected Tropical Diseases, by Indication, 2015-2021
  • Table 1 : Key Trends in Neglected Tropical Diseases

3: Disease Overview

  • Malaria
  • Leishmaniasis
  • Schistosomiasis
  • Lymphatic Filariasis
  • Chagas Disease
  • African Trypanosomiasis
  • Dengue
  • Ebola
  • Zika

4: Market Overview

  • Total Addressable Market
  • Malaria
  • Leishmaniasis
  • Schistosomiasis
  • Lymphatic Filariasis
  • Chagas Disease
  • African Trypanosomiasis
  • Dengue
  • Ebola
  • Zika
  • Donations by Pharmaceutical Companies: Access to Medicines

5: Market Influencing Factors

  • Market Drivers
  • Market Deterrents
  • Unmet Needs

6: Research and Development

  • Malaria
  • Leishmaniasis
  • Schistosomiasis
  • Lymphatic Filariasis
  • Chagas Disease
  • African Trypanosomiasis
  • Dengue
  • Ebola
  • Zika

7: Patent Review

  • Malaria
  • Leishmaniasis
  • Schistosomiasis
  • Lymphatic Filariasis
  • Chagas Disease
  • African Trypanosomiasis
  • Dengue
  • Ebola
  • Zika

8: Company Profiles

  • Anacor Pharmaceuticals (Now Pfizer)
  • Bayer
  • Butantan
  • (DNDI) Drugs For Neglected Diseases Initiative
  • Eisai
  • Gilead Sciences
  • Glaxosmithkline
  • Merck
  • (MMV) Medicines For Malaria Venture
  • Novartis
  • The Path Malaria Vaccine Initiative
  • Sabin Vaccine Institute
  • Sanofi-Aventis/Sanofi Pasteur
  • Takeda

9: Appendix: Abbreviations

  • Table 76 : Abbreviations Used in Neglected Tropical Diseases Landscape
  • Table 77 : Glossary of Terms Used in Neglected Tropical Diseases Landscape
  • Table 78 : Report Sources

List of Tables

Summary Table : Global Market for Neglected Tropical Diseases, by Indication, Through 2021
Table 1 : Key Trends in Neglected Tropical Diseases
Table 2 : Estimated Malaria Incidence (per 1,000 at Risk), 2000-2015
Table 3 : Suspected Malaria Cases, 2010-2015
Table 4 : Confirmed Malaria Cases, 2010-2015
Table 5 : Estimated Spending on Malaria Treatment in Sub-Saharan Africa, 2010-2014
Table 6 : WHO Guidelines for Treatment of Malaria
Table 7 : Number of Cases of CL in Select High Burden Countries, 2010-2014
Table 8 : Number of Cases of VL in Select High Burden Countries, 2010-2014
Table 9 : Incidence of CL and VL in High Burden Countries, 2014
Table 10 : Global Disease Burden of Leishmaniasis, 2015
Table 11 : WHO Guidelines for Treatment of Leishmaniasis
Table 12 : Number of People Treated Globally, 2010-2014
Table 13 : Global Disease Burden of Schistosomiasis, 2015
Table 14 : Global Disease Burden of Lymphatic Filariasis, 2015
Table 15 : Prevalence and Incidence (Number) of Chagas Disease, 2015
Table 16 : Global Disease Burden of Chagas Disease, 2015
Table 17 : Prevalence and Incidence (Number) of Chagas Disease, 2015
Table 18 : Global Disease Burden of African Trypanosomiasis, 2015
Table 19 : Prevalence and Incidence (Number) of Dengue Cases, 2015
Table 20 : Reported Cases and Deaths in Ebola Outbreaks, 2007-2016
Table 21 : Zika Burden, 2015-2016
Table 22 : Global Addressable Market for Neglected Tropical Diseases, by Indication, Through 2021
Table 23 : Global Addressable Market for Malaria, by Region, Through 2021
Table 24 : Global Addressable Market for Leishmaniasis, by Region, Through 2021
Table 25 : Global Addressable Market for Schistosomiasis, by Region, Through 2021
Table 26 : Global Addressable Market for Lymphatic Filariasis, by Region, Through 2021
Table 27 : Global Addressable Market for Chagas Disease, by Geography, Through 2021
Table 28 : Global Addressable Market for Dengue, by Region, Through 2021
Table 29 : Global Addressable Market for Zika, by Region, Through 2021
Table 30 : Drug Donation Commitments, by WHO
Table 31 : Malaria Development Pipeline and Recent Launches
Table 32 : Leishmaniasis Development Pipeline and Recent Launches
Table 33 : Schistosomiasis Development Pipeline and Recent Launches
Table 34 : Lymphatic Filariasis Development Pipeline and Recent Launches
Table 35 : Chagas Disease Development Pipeline and Recent Launches
Table 36 : African Trypanosomiasis Development Pipeline and Recent Launches
Table 37 : Dengue Development Pipeline and Recent Launches
Table 38 : Ebola Development Pipeline and Recent Launches
Table 39 : Zika Development Pipeline and Recent Launches
Table 40 : Number of Patent Applications, Malaria, by Assignee
Table 41 : Number of Patent Applications, Malaria, by Year, 2010-2015
Table 42 : Number of Patent Applications, Malaria, by Country
Table 43 : Number of Patent Applications, Malaria, by Type
Table 44 : Number of Patent Applications, Leishmaniasis, by Assignee
Table 45 : Number of Patent Applications, Leishmaniasis, by Year, 2010-2015
Table 46 : Number of Patent Applications, Leishmaniasis, by Country
Table 47 : Number of Patent Applications, Leishmaniasis, by Type
Table 48 : Number of Patent Applications, Schistosomiasis, by Assignee
Table 49 : Number of Patent Applications, Schistosomiasis, by Year, 2010-2015
Table 50 : Number of Patent Applications, Schistosomiasis, by Country
Table 51 : Number of Patent Applications, Schistosomiasis, by Type
Table 52 : Number of Patent Applications, Lymphatic Filariasis, by Assignee
Table 53 : Number of Patent Applications, Lymphatic Filariasis, by Year, 2010-2015
Table 54 : Number of Patent Applications, Lymphatic Filariasis, by Country
Table 55 : Number of Patent Applications, Lymphatic Filariasis, by Type
Table 56 : Number of Patent Applications, Chagas Disease, by Assignee
Table 57 : Number of Patent Applications, Chagas Disease, by Year, 2010-2015
Table 58 : Number of Patent Applications, Chagas Disease, by Country
Table 59 : Number of Patent Applications, Chagas Disease, by Type
Table 60 : Number of Patent Applications, African Trypanosomiasis, by Assignee
Table 61 : Number of Patent Applications, African Trypanosomiasis, by Year, 2010-2015
Table 62 : Number of Patent Applications, African Trypanosomiasis, by Country
Table 63 : Number of Patent Applications, African Trypanosomiasis, by Type
Table 64 : Number of Patent Applications, Dengue, by Assignee
Table 65 : Number of Patent Applications, Dengue, by Year, 2010-2015
Table 66 : Number of Patent Applications, Dengue, by Country
Table 67 : Number of Patent Applications, Dengue, by Type
Table 68 : Number of Patent Applications, Ebola, by Assignee
Table 69 : Number of Patent Applications, Ebola, by Year, 2010-2016
Table 70 : Number of Patent Applications, Ebola, by Country
Table 71 : Number of Patent Applications, Ebola, by Type
Table 72 : Number of Patent Applications, Zika, by Assignee
Table 73 : Number of Patent Applications, Zika, by Year, 2010-2016
Table 74 : Number of Patent Applications, Zika, by Country
Table 75 : Number of Patent Applications, Zika, by Type
Table 76 : Abbreviations Used in Neglected Tropical Diseases Landscape
Table 77 : Glossary of Terms Used in Neglected Tropical Diseases Landscape
Table 78 : Report Sources

List of Figures

Summary Figure : Global Market for Neglected Tropical Diseases, by Indication, 2015-2021
Figure 1 : Global Number of Malaria Caused Deaths, 2011-2015
Figure 2 : Global Number of Leishmaniasis Caused Deaths, 2011-2015
Figure 3 : Global Leishmaniasis Years of Life Lost*, 2011-2015
Figure 4 : Global Number of Schistosomiasis Caused Deaths, 2011-2015
Figure 5 : Global Schistosomiasis Years of Life Lost*, 2011-2015
Figure 6 : Number of Lymphatic Filariasis Endemic Countries, by Region
Figure 7 : Number of Chagas Disease Caused Deaths, 2011-2015
Figure 8 : Global Chagas Disease Years of Life Lost*, 2011-2015
Figure 9 : Number of Cases of African Trypanosomiasis, T.b. gambiense, 2011-2015
Figure 10 : Number of Cases of African Trypanosomiasis, T.b. rhodesiense, 2011-2015
Figure 11 : Global Number of African Trypanosomiasis Caused Deaths, 2011-2015
Figure 12 : Global African Trypanosomiasis Years of Life Lost*, 2011-2015
Figure 13 : Average Annual Number of Dengue Fever Cases, 1960-2007
Figure 14 : Number of Cases in American Region, 2012-2016
Figure 15 : Incidence Rate (per 100,000 Inhabitants) in American Region, 2012-2016
Figure 16 : Global Number of Dengue Caused Deaths, 2011-2015
Figure 17 : Global Dengue Caused Years of Life Lost*, 2011-2015
Figure 18 : Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number of Cases, March 2014-February 2016
Figure 19 : Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number of Deaths, March 2014-February 2016
Figure 20 : Number of Countries (Y) with Number of Confirmed Zika Cases (X), by American Region, 2015-2016
Figure 21 : Global Addressable Market for Neglected Tropical Diseases, by Indication, 2015-2021
Figure 22 : Global Market for Malaria, by Region, 2014-2021
Figure 23 : Global Market for Leishmaniasis, by Region, 2014-2021
Figure 24 : Global Market for Schistosomiasis, by Region, 2014-2021
Figure 25 : Global Market for Lymphatic Filariasis, by Region, 2014-2021
Figure 26 : Global Market for Chagas Disease, by Geography, 2014-2021
Figure 27 : Global Market for Dengue, by Region, 2014-2021
Figure 28 : Global Market for Zika, by Region, 2014-2021
Figure 29 : Clinical Trials in Malaria, by Intervention Type, January 2005-September 2016
Figure 30 : Top 20 Sponsors/Collaborators, by Clinical Trials in Malaria, January 2005-September 2016
Figure 31 : Clinical Trials in Leishmaniasis, by Intervention Type, January 2005-September 2016
Figure 32 : Key Sponsors/Collaborators, Clinical Trials in Leishmaniasis, January 2005-September 2016
Figure 33 : Clinical Trials in Schistosomiasis, by Intervention Type, January 2005-September 2016
Figure 34 : Key Sponsors/Collaborators, Clinical Trials in Lymphatic Filariasis, January 2005-September 2016
Figure 35 : Clinical Trials in Chagas Disease, by Intervention Type, January 2005-September 2016
Figure 36 : Key Sponsors/Collaborators, Clinical Trials in Chagas Disease, January 2005-September 2016
Figure 37 : Clinical Trials in Dengue, by Intervention Type, January 2005-September 2016
Figure 38 : Key Sponsors/Collaborators, Clinical Trials in Dengue, January 2005-September 2016
Figure 39 : Clinical Trials in Ebola, by Intervention Type, January 2005-September 2016
Figure 40 : Key Sponsors/Collaborators, Clinical Trials in Ebola, January 2005-September 2016
Figure 41 : Key Sponsors/Collaborators, Clinical Trials in Zika, January 2005-September 2016
Figure 42 : Patent Share for Treatment and Preventive Medicine in Malaria, by Year
Figure 43 : Patent Share for Treatment and Preventive Medicine in Malaria, US and non-US
Figure 44 : Patent Share for Treatment and Preventive Medicine in Leishmaniasis, by Year
Figure 45 : Patent Share for Leishmaniasis, US and non-US
Figure 46 : Patent Share for Treatment and Preventive Medicine in Schistosomiasis, by Year
Figure 47 : Patent Share for Schistosomiasis, U.S. and non-U.S.
Figure 48 : Patent Share for Treatment and Preventive Medicine in Lymphatic Filariasis, by Year
Figure 49 : Patent Share for Lymphatic Filariasis, U.S. and non-U.S.
Figure 50 : Patent Share for Treatment and Preventive Medicine in Chagas Disease, by Year
Figure 51 : Patent Share for Chagas Disease, by U.S. and non-U.S.
Figure 52 : Patent Share for Treatment and Preventive Medicine in African Trypanosomiasis, by Year
Figure 53 : Patent Share for African Trypanosomiasis, US and non-US
Figure 54 : Patent Share for Treatment and Preventive Medicine in Dengue, by Year
Figure 55 : Patent Share for Dengue, U.S. and non-U.S.
Figure 56 : Patent Share for Treatment and Preventive Medicine in Ebola, by Year
Figure 57 : Patent Share for Ebola, U.S. and non-U.S.
Figure 58 : Patent Share for Treatment and Preventive Medicine in Zika, by Year
Figure 59 : Patent Share for Zika, U.S. and Non-U.S.
Figure 60 : DNDi - Research Portfolio, by Phase of Development
Figure 61 : DNDi - Research Portfolio, by Indication
Figure 62 : GlaxoSmithKline - Research Portfolio, by Phase of Development
Figure 63 : GlaxoSmithKline - Research Portfolio, by Indication
Figure 64 : MMV - Research Portfolio, by Phase of Development
Figure 65 : MMV - Research Portfolio, by Partner

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Bayer
  • Butantan
  • Eisai
  • Gilead Sciences
  • Glaxosmithkline
  • Merck
  • MORE

Analyst's Credentials:

Ms. Joshi has a master’s degree in biotechnology from the Indian Institute of Technology (IIT Mumbai) and a diploma in management consulting from the Consultancy Development Centre of the Department of Scientific and Industrial Research, India. She has more than seven years experience in the fields of competitive intelligence, technology strategy, market research and patent analysis in the pharmaceutical, biotechnology and agrochemical industries. She has also worked as a technology prospecting platform manager for Monsanto.

Note: Product cover images may vary from those shown
5 of 6
  • Anacor Pharmaceuticals (Now Pfizer)
  • Bayer
  • Butantan
  • (DNDI) Drugs For Neglected Diseases Initiative
  • Eisai
  • Gilead Sciences
  • Glaxosmithkline
  • Merck
  • (MMV) Medicines For Malaria Venture
  • Novartis
  • The Path Malaria Vaccine Initiative
  • Sabin Vaccine Institute
  • Sanofi-Aventis/Sanofi Pasteur
  • Takeda
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll